Related Experiment Videos
[Pharmacokinetics of ceftazidime in newborn infants]
R Rule1, N J Martiarena, M Rubio
1Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Buenos Aires, Argentina.
Insights
This study details ceftazidime pharmacokinetics in premature infants with pneumonia. Dosing recommendations were established for treating bacterial infections, ensuring effective antibiotic levels in this vulnerable population.
Area of Science:
- Pharmacokinetics
- Neonatal Pharmacology
- Antibiotic Therapy
Context:
- Neonatal pneumonia presents unique challenges for antibiotic dosing.
- Premature infants have altered drug metabolism and excretion.
- Accurate pharmacokinetic data is crucial for effective treatment.
Purpose:
- To characterize the pharmacokinetic profile of ceftazidime in premature infants.
- To determine optimal loading and maintenance doses for common pathogens.
- To ensure therapeutic drug concentrations and minimize toxicity.
Summary:
- A pharmacokinetic study of ceftazidime was conducted in six premature infants (body weight ≤2000 g) with pneumonia.
- Intravenous ceftazidime (50 mg/kg) was administered, with plasma concentrations analyzed via HPLC.
- Key pharmacokinetic parameters including half-life (4.05 ± 0.81 h) and clearance (114.9 ± 30.0 ml/h·kg) were determined.
- Calculated loading and maintenance doses for Enterobacteriaceae and P. aeruginosa were 15 mg/kg and 13 mg/kg every 12 hours, respectively.
Impact:
- Provides essential pharmacokinetic data for ceftazidime in neonates.
- Informs evidence-based dosing strategies for treating neonatal infections.
- Aims to improve treatment outcomes and reduce antibiotic resistance.
Abstract:
A pharmacokinetic study of ceftazidime was performed in newborn children. Six premature infants with a body weight up to 2000 g and with symptoms of pneumonia (Table 1) were treated with ceftazidime (50 mg/kg body weight) by endovenous route. Plasma concentrations of the antibiotic (Fig. 1) were determined by HPLC. A kinetic behavior was described through a compartment model independent analysis. The calculated parameters were as follows: half-life (T1/2z = 4.05 +/- 0.81 h) apparent volume of distribution (Vz = 686.0 +/- 258.6 ml/kg), elimination rate constant (lambda z = 0.18 +/- 0.04h-1), area under curve (AUC = 464.4 +/- 139.1 mu gh/ml, mean residence time (MRT = 5.2 +/- 1.3 h), and total clearance (CI = 114.9 +/- 30.0 ml/h. kg) (Table 2). Good correlation was observed (r = 0.83, p < 0.05 between lambda z = and Vz). The loading and maintenance doses calculated for enterobacteria and P. aeruginosa were 15 and 13 mg/kg i.v. respectively each 12 h.